TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Normal vessels' diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal peak flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumor lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of daily topical application of norepinephrine
Endpoint domain: Adverse events/effects
Primary endpoint: Pain average reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of Masimo SpHb Butterfly Sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients with dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Preliminary efficacy determination as evaluated by disease specific response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic progression free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of myocardial function and contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MACE at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Steady-state Plasma Concentration-time Curve (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Active-knee-extension test (AKE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Straight-leg-raise test (SLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of crowding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular inflammatory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: NAFLD status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Epicardial adipose tissue status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of platelets activation markers expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Professional Fulfillment Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PERMA 15-item Self-scoring Instrument
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Implementation leadership scale (ILS)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Average hot flash score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tilt angle of distal radius growth plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life as measured by SF36 subscales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Treatment-Emergent Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Peak plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fMRI: Social Reward Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in abdominal pain or discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in 24-hour urinary risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of upper gastrointestinal clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Agreement between diagnostic methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Positive Schizophrenia Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Global Social Functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean Ocular Coma Score at 5mm Pupil at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cured PMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MADRS total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain Threshold at Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Northwick Park Questionnaire for Cervical Spine disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Absolute Change From Baseline in HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in the 16-Item Negative Symptoms Assessment (NSA-16)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: biochemically confirmed post treatment smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AR-12
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Continuous Clinical Response (pCCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermal Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: AIDS Risk Behavior Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of units of blood donated by the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of units of donor blood transfused during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total red cell volume and percentage in self-donated blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of sub-standard units of blood self-donated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: diabetes and insulin injection related knowledge scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: insulin injection skills scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-efficacy in insulin injection scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with a DoT to Stivarga of more than 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting New Onset Chronic Medical Conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Infant Participants Reporting Solicited Systemic Adverse Events Within 11 Days of Maternal Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of bacteriologically confirmed TB recurrence cases
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of HBV vaccination series
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Responded
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuron Specific Enolase (NSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S100A12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium Binding Protein Beta (S100B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glial Fibrillary Acidic Protein (GFAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocyte Chemoattractant Protein (MCP1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dyspnea Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in 24-Hour Average Pain Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: clinical, blood and/or genetic markers of PCOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful apheresis collection of CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death and re-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Severity of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants with at Least One ≥ Grade 3 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Simplified disease activity index (SDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practice adherence to diabetes guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: level of ATP production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Steroidogenesis associated enzymatic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal plasma concentration (Cmax) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma HAI titer at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic uptake and washout of 123-I AV39
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Ongoing pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Abnormal birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cesarean sections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Comparison of diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability for Movement Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of first and second stages of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Qualitative MALT-features on Endomicroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma HIV-RNA < 400 cop/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who receive influenza vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perceived pain-related functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of moderate or severe AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Wounds With Complete Skin Graft Take
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with adverse events with grade 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: Preferences for medical care regarding CPR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Are Lice Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Feedback-related positivity (FRP) amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-related negativity (ERN) amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Performance on the Probabilistic Reward Task (PRT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patients' opinions regarding compliance monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of acute coronary syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of acute cerebral syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete rate of LTBI treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PD-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of malignant cases in subsequent thyroidectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acceptability of At-home Self-collection for HPV Testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With an Objective Response (PR + CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: left foot volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of anterior open bite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Modified Oswestry Disability Index (MODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Best corrected distance visual acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of neurological deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of intraoperative maternal hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ephedrine requirement during spinal anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure of Bacterial Vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term tolerability of Asfotase Alfa
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy in treating rickets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adult ADHD Investigator Symptom Rating Scale - Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARDS Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of antibiotic-associated diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Risk perception of physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Self Report an Average of Zero Cigarettes Smoked Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin scale (mRS) 0-1 (favourable outcome)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL (Normoresponder)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL (Hyporesponsive)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With a Mean Hb Above 11 g/dL (Weeks 17-20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in specific antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of mild or moderate flares of SLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of averted PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: clearance of jaundice (<20 umol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion transplanted or died
Endpoint domain: Mortality/survival
Primary endpoint: progress free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: tolerance of enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time oral intake started
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft Failure Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Neuroendocrine status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cognitive capability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Physical capability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post-ERCP Pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Torso motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean sum of primary pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in mean common carotid intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ICS dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoxifen blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sex in the last 90 days
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pain Disability Index (PDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disease Activity Scale (DAS)28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adherence levels to antiretroviral treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaginal health index score (VHIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female sexual function index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Change from baseline in plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in CD4+ cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of neonatal sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ventilator days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication Possession Ratio at Baseline
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Medication Possession Ratio at 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction of bioburden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to prescribed post-operative incentive spirometer exercises
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average score from the PADQ-E
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average score from the Readiness for Hospital Discharge Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction as measured by the Press Ganey Consumer Assessment of Healthcare Providers and Systems Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in symptoms of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline to Week 24 in Distance Walked as Assessed by the Six-minute Walk Test (6MWT) Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Daily Step Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 24 Scores on the Beck Depression Inventory II (BDI-II) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urine lactulose:mannitol (L:M) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in ejection fraction after 24 training sessions (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes